G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Relative Value

The Relative Value of one GLS stock under the Base Case scenario is 815.23 INR. Compared to the current market price of 1 045.65 INR, Glenmark Life Sciences Ltd is Overvalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLS Relative Value
Base Case
815.23 INR
Overvaluation 22%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
4
vs Industry
28
Median 3Y
3.1
Median 5Y
3.1
Industry
2.5
Forward
5.2
vs History
4
vs Industry
21
Median 3Y
14.3
Median 5Y
14.3
Industry
21.9
Forward
25.6
vs History
2
vs Industry
17
Median 3Y
16.7
Median 5Y
15.7
Industry
16.5
vs History
7
vs Industry
14
Median 3Y
25.1
Median 5Y
24.7
Industry
23.6
vs History
4
vs Industry
17
Median 3Y
3.3
Median 5Y
3.3
Industry
2.1
vs History
4
vs Industry
27
Median 3Y
2.9
Median 5Y
2.9
Industry
2.6
Forward
4.9
vs History
4
vs Industry
27
Median 3Y
5.5
Median 5Y
5.5
Industry
5.2
vs History
4
vs Industry
25
Median 3Y
9.8
Median 5Y
9.8
Industry
13.3
Forward
17.2
vs History
4
vs Industry
26
Median 3Y
10
Median 5Y
10
Industry
16.6
Forward
18.1
vs History
2
vs Industry
19
Median 3Y
15.6
Median 5Y
14.6
Industry
15.6
vs History
7
vs Industry
13
Median 3Y
23.4
Median 5Y
22.7
Industry
19.1
vs History
2
vs Industry
18
Median 3Y
3.6
Median 5Y
3.5
Industry
1.9

Multiples Across Competitors

GLS Competitors Multiples
Glenmark Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Glenmark Life Sciences Ltd
NSE:GLS
128.1B INR 5.8 30.3 20.2 22.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
IN
G
Glenmark Life Sciences Ltd
NSE:GLS
Average P/E: 32.1
30.3
50%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top